Free Trial
LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
55
55
52-Week Range
N/A
Volume
70,791 shs
Average Volume
150,610 shs
Market Capitalization
£228 million
Assets Under Management
N/A
Dividend Yield
N/A
Net Expense Ratio
0.00%
VRP stock logo

About Verona Pharma plc (VRP.L) (LON:VRP)

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

VRP ETF News Headlines

Dave Ramsey Makes Big Mistake Live On Air
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
Verona Pharma plc (VRNA)
Michael Austwick Joins Verona Pharma as Non-Executive Director
Dave Ramsey Makes Big Mistake Live On Air
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
BTIG Keeps Their Buy Rating on Verona Pharma (VRNA)
See More Headlines
Receive VRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Verona Pharma plc (VRP.L) (VRP)

Key Executives

  • Dr. Jan-Anders Karlsson (Age 64)
    CEO & Exec. Director
  • Mr. Piers John Morgan (Age 53)
    Chief Financial Officer
  • Ms. Claire Louise Poll L.C.S.W. (Age 52)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Dr. Peter Spargo (Age 57)
    Sr. VP of Chemistry Manufacturing & Controls

VRP ETF - Frequently Asked Questions

How were Verona Pharma plc (VRP.L)'s earnings last quarter?

Verona Pharma plc (VRP.L) (LON:VRP) posted its earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($30.80) by $0.50.

How do I buy shares of Verona Pharma plc (VRP.L)?

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Verona Pharma plc (VRP.L) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

This page (LON:VRP) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners